Alexis JANIN’s Post

While we have always been very deep in terms of our understanding of healthcare & life sciences sector, last year our team at Healthark Insights decided to start getting even deeper in terms of how we track the sector, and start publishing our insights at a therapeutic area level. We started last year with oncology sector, publishing an annual report called the 'Cancer Compass'. Building further on the success of cancer compass, we are really excited to launch our next annual publication named 'Immunology Compass'. Global spending in #immunology treatment reached USD 160 billion in 2023 - attributed to surging prevalence of auto-immune disorders, widespread adoption of #biologics and #biosimilars, and successful clinical trials leading to the development of novel therapeutics. There are a series of blockbuster drugs, mergers & acquisitions, interesting trends and other critical developments in the space. Check out Healthark Insights' report, 'Immunology Compass' - your go-to business handbook for the Immunology industry! Shivang Bhagat Pruthvi Bhanabhagawanwala Ishita Shah #healthark #immunology #immunologycompass #lifesciences #healthcare

Pharma has been busy! As this season of industry conventions and conferences suggests (enthusiastic applause in some sessions!), innovation remains in high gear – creating benefits for all of us; and investment opportunities galore – also bearing great promises. That’s good news in light of interest rates still a tad high, development costs in the multi-billions for innovative Rx drugs, and at a time where the industry continues to feel under cost pressure. With ASCO wrapped up earlier this week, we know more about some of the frontier-breaking advances in breast cancer, lung cancer, and multiple myeloma, likely resulting in changes to standards of care. And with BIO ending yesterday, we can expect further M&A, and with increased focus on clinical-stage firms. So now then is the time to ensure that assets progress to market swiftly, that providers are informed about differentiation effectively, that insurers cover new treatments comprehensively - and that patients can benefit substantially – be relieved of symptoms, experience fewer side effects, and live longer. And on the pharma strategy and portfolio side, it is good practice after conferences like this to refresh therapeutic area landscapes, to optimize for efficient clinical development, and to shape pipelines and target lists for ever more focused franchises. Here at Deallus, we’re on it – and energized, with numerous consultants analyzing conference presentations, with senior leaders partnering with big pharma clients deriving strategic implications, and with global capabilities built to offer quasi real-time intel on important developments in these dynamic markets. #ASCO #BIO2024 #pharmaindustry #competitiveintelligence #Deallus #Oncology #Cancer

“Aptadir’s business is based on real innovation—a landmark discovery of a new class of molecules which have the potential to be best-in-class therapeutics for intractable conditions,” Giovanni Amabile, CEO of Aptadir Therapeutics said in a Sept. 24 release. The biotech world is buzzing with Aptadir Therapeutics’s breakthrough in RNA inhibitors, which could revolutionize the fight against notoriously tricky cancers. With a novel approach to reversing conditions that have long been considered unmanageable, this is a game-changer in the development of best-in-class therapies. Backed by $34 million in series A funding, Aptadir is preparing to advance its preclinical work, aiming to enter clinical trials by 2026. This level of support from prominent investors like Sofinnova Partners and 3B Future Health Fund I & II underscores the confidence in their potential to tackle some of the most complex cancer cases. It will be exciting to follow their progress as they move from discovery to application. CDP Venture Capital SGR Claudia Pingue Angelini Ventures Paolo Di Giorgio Evotec Vittorio de Franciscis Italian National Research Council Daniel Tenen Marcin Kortylewski #Biotech #Innovation #CancerTherapy #RNA #Therapeutics #Funding #ClinicalTrials

Spartan Capital Securities, LLC is excited to welcome NeuroSense Therapeutics as a presenting company at the Spartan Capital Investor Conference 2024, taking place on November 4th at The Pierre Hotel in New York City.   NeuroSense Therapeutics, Ltd. (Nasdaq:NRSN) is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases. NeuroSense Therapeutics's leadership team includes Alon Ben-Noon 🇮🇱, Ferenc Tracik, MD, Niva Russek- Blum, Hagit Binder, Or Eisenberg, Sharon Cohen-Vered, Diana S., Shiran Zimri, Yael Barak, Nedira Salzman-Frenkel, Dorit Jacob, Vered Sasson 🇮🇱, Eidan Loushi, Nitai Kerem, Keren Pushett and many other talented individuals including Natalya Rudman at crescendo-ir.com. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities.   To secure your place at this premier event, visit: https://lnkd.in/enQCABXZ   #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024

I vividly remember February 15, 2018, when Roche closed a Series C round, acquiring Flatiron Health for $1.9 billion and integrating it as a subsidiary while allowing it to operate as a separate legal entity. Two years prior, Roche had completed the acquisition of a 62.8% stake in Foundation Medicine Inc. -Cohomprensive Genomic Profile Test (Next Gen. Seq.) - , a company based in Cambridge, Massachusetts, near Boston. These acquisitions represented different business models compared to Roche’s traditional value chain. As part of my executive MBA at POLIMI Graduate School of Management, we decided to develop a #projectwork on "revising the business model to create an end-to-end integration of clinical and #genomic data from #NGS ( Next Generation Sequencing) tests #EHRs and #RWD. We highlighted the challenges and proposed solutions to manage different asset and Innovative solutions as traditional DrugMaker Company. Today, thanks to #syntheticdata, everything is much simpler and probably Flatiron need to evaluate scaling and internationalization approaches. Reading the recent news about Roche’s desire to review its agreements with Flatiron, I feel nostalgic and hopeful that companies like Flatiron or Syapse, also in Roche’s current investment portfolio, can find integration solutions through a redesigned Go-to-Patient and Go-to-Market model. This would enhance the future portfolio and pipeline value. Thanks again to Prof. Emanuele Lettieri and Prof. Federico Frattini, who contributed to that work, which remains valuable today for the principles of revising #businessmodels in drug innovation and #InnovativeHealthSolutions support of the portfolio strategy. Special thanks to my EMBA mates that contributed to reading, inspiring, driving, writing, having fun, think, smiling, leading, ..... Stefano Allevi | Andrea Carrettoni | Davide Mazzali - EMBA | Alessandro Braga | Marco Berci | Pietro Ponti | Alessandro Sapio | Matteo Vecchio | A huge thank you goes to the #leaders and #enablers of that time - Patrizia Olivari | Adriana Dantas | Pedro Goncalves | Alessandra Bianchi | Diego Vailati Venturi | Maurizio de Cicco - who, as visionary leaders, saw the future and the tangible impact on patients lives, allowing me to work on this model.

Exciting News in the T-Cell Engager Space! Ken Song's Candid Therapeutics has just made headlines by raising a phenomenal $370 million to kickstart his new venture! This ground-breaking investment underscores the massive potential and growing interest in T-Cell engager therapies—a rapidly evolving frontier in immunotherapy. Candid Therapeutics is at the forefront of this innovative field, pushing the boundaries of how we approach autoimmune diseases. Their work is not just advancing science; it's paving the way for new hope for patients worldwide. Stay tuned for more updates on how this exciting new venture develops. #Biotech #Immunotherapy #TCellEngagers #CandidTherapeutics #Innovation #Healthcare #FundingNews

In the dynamic world of pharma, the dance of M&A is often the unsung hero behind your medicine cabinet staples. 💡💊 From groundbreaking cancer drugs to essential anti-inflammatories, strategic deals have been pivotal. The last decade's end was a M&A bonanza, with big pharma courting innovative BioTech's. Focus areas? Cancer, rare diseases, immune disorders - where clinical triumphs often translate into market treasures. 🎯 After a lull in 2021-2022, deal-making's back with a vengeance, eyeing obesity, next-gen tech, and even the once-shunned neuroscience. 🧠💼 Staying updated on M&A activity is crucial. It's not just about figures; it's about foreseeing where the next wave of life-changing treatments might emerge from. ➡️ Remember, behind every merger, there's a potential medical marvel waiting to happen. #PharmaMandA #Innovation #HealthcareTrends

Spartan Capital Securities, LLC is excited to welcome NeuroSense Therapeutics as a presenting company at the Spartan Capital Investor Conference 2024, taking place on November 4th at The Pierre Hotel in New York City.   NeuroSense Therapeutics, Ltd. (Nasdaq:NRSN) is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases. NeuroSense Therapeutics's leadership team includes Alon Ben-Noon 🇮🇱, Ferenc Tracik, MD, Niva Russek- Blum, Hagit Binder, Or Eisenberg, Sharon Cohen-Vered, Diana S., Shiran Zimri, Yael Barak, Nedira Salzman-Frenkel, Dorit Jacob, Vered Sasson 🇮🇱, Eidan Loushi, Nitai Kerem, Keren Pushett and many other talented individuals including Natalya Rudman at crescendo-ir.com. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities.   To secure your place at this premier event, visit: https://lnkd.in/enQCABXZ   #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024

[#Healthcare] Kurma Partners, group’s asset manager focused on improving human health, has successfully raised €140 million for the first closing of Biofund IV, with a target of €250 million by 2025. Eurazeo is proud to be a cornerstone investor alongside Bpifrance, CSL, and other key partners. 💡 Biofund IV will support 16 to 20 innovative companies developing groundbreaking therapeutics, combining company creation with investments in venture-stage businesses. The fund has already made its first three investments in SciRhom, Memo Therapeutics AG, and Avidicure, targeting autoimmune diseases, natural immunity, and cancer immunotherapy. 🏥 Building on the success of Biofund III, Kurma continues its collaborative approach by working with leading academic scientists and industry professionals to create the next generation of healthcare solutions. This new fund reinforces Kurma’s proven venture model and strengthens Eurazeo’s commitment to driving innovation and growth in healthcare. #VentureCapital #HealthcareInnovation #Therapeutics #HealthEconomy #Biofund

Switzerland is undoubtedly a lucrative destination for biotech investment. Labiotech.eu's recent article highlights Switzerland's rising prominence as a global leader in biotechnology, supported by its breathtaking landscapes and exceptional cuisine. Swiss biotech companies are often at the forefront of developing cutting-edge treatments across healthcare, including oncology, immunotherapy and regenerative medicine. We’ve delved into some of the top biotech firms from the article’s list of 18, including Alentis Therapeutics, Endogena Therapeutics, Inc., and STALICLA, that are leading the charge in revolutionising healthcare. Swipe through to explore their ground-breaking innovations, and connect with Hobson Prior for further insights into the biotech industry and exciting career opportunities: https://www.hobsonprior.ch Read the full article here to find out who else made the list: https://lnkd.in/gnPbAhQ #SwissBiotech #Oncology #Immunotherapy #BiotechInnovation #Healthcare #Switzerland #LifeSciences